about
Effects of aminoguanidine and melatonin on intestinal ischemia/reperfusion injury in rats: An assessor-blinded, controlled experimental study.Ozonated olive oils and the troubles.Epigenetic perturbations in the pathogenesis of mustard toxicity; hypothesis and preliminary results.Ozone therapy and hyperbaric oxygen treatment in lung injury in septic rats.Effect of hyperbaric oxygen and ozone preconditioning on oxidative/nitrosative stress induced by tourniquet ischemia/reperfusion in rat skeletal muscle.Poly(ADP-ribose) polymerase inhibition modulates experimental acute necrotizing pancreatitis-induced oxidative stress, bacterial translocation and neopterin concentrations in rats.Protective effects of angiotensin II type-1 receptor blockade with olmesartan on spinal cord ischemia-reperfusion injury: an experimental study on rats.Effects of medical ozone therapy on acetaminophen-induced nephrotoxicity in rats.3-aminobenzamide, a poly ADP ribose polymerase inhibitor, attenuates renal ischemia/reperfusion injury.Efficacy of hyperbaric oxygen therapy and medical ozone therapy in experimental acute necrotizing pancreatitis.Comparison of the efficacy of melatonin and 1400W on renal ischemia/reperfusion injury: a role for inhibiting iNOS.Medical ozone therapy reduces oxidative stress and intestinal damage in an experimental model of necrotizing enterocolitis in neonatal rats.Melatonin prevents peritoneal adhesions in rats.All-trans-retinoic acid attenuates intestinal injury in a neonatal rat model of necrotizing enterocolitis.PARP inhibition prevents acetaminophen-induced liver injury and increases survival rate in rats.The protective effect of melatonin and S-methylisothiourea treatments in nitrogen mustard induced lung toxicity in rats.Long-term exposure to repetitive hyperbaric oxygen results in cumulative oxidative stress in rat lung tissue.Comparison of hyperbaric oxygen and medical ozone therapies in a rat model of experimental distal colitis.Protective effects of colchicine in an experimental model of necrotizing enterocolitis in neonatal rats.Ozone ameliorates methotrexate-induced intestinal injury in rats.Erdosteine and ebselen as useful agents in intestinal ischemia/reperfusion injury.Proanthocyanidin protects intestine and remote organs against mesenteric ischemia/reperfusion injury.Melatonin and 1400 W ameliorate both intestinal and remote organ injury following mesenteric ischemia/reperfusion.Hyperbaric oxygen therapy reduces the severity of necrotizing enterocolitis in a neonatal rat model.Inhibition of iNOS reduces the therapeutic effects of ozone in acute necrotizing pancreatitis: an in vivo animal study.Evaluation of the effect of cola drinks on bone mineral density and associated factors.Ameliorative effects of proanthocyanidin on renal ischemia/reperfusion injury.Scavenging of peroxynitrite reduces renal ischemia/reperfusion injury.Effect of 3-amino benzamide, a poly(adenosine diphosphate-ribose) polymerase inhibitor, in experimental caustic esophageal burn.Establishing the use of melatonin as an adjuvant therapeutic against paraquat-induced lung toxicity in rats.Oxidative stress levels in rats following exposure to oxygen at 3 atm for 0-120 min.The relation between oxidative stress, inflammation, and neopterin in the paraquat-induced lung toxicity.Beneficial effects of Etanercept on experimental necrotizing enterocolitis.Evaluation and comparison of the effect of hypothermia and ozone on ischemia-reperfusion injury of skeletal muscle in rats.Persistence of hyperbaric oxygen-induced oxidative effects after exposure in rat brain cortex tissue.Antioxidant effects of melatonin in rats during chronic exposure to hyperbaric oxygen.Medical ozone therapy decreases postoperative uterine adhesion formation in rats.Passive smoke exposure of female rats caused aortic atherosclerotic precursor lesions in their offspring.Time-dependent course of hyperbaric oxygen-induced oxidative effects in rat lung and erythrocytes.A new utilization area for hyperbaric oxygen? Improving quality of stored blood.
P50
Q38560692-DF53B2AD-CE80-4F91-9410-01C3B3F0F5D9Q40507741-3505C0DD-05B8-4117-92CE-0F3849235A24Q41430037-46C05CE9-C0B1-4DEF-A839-9B6DE733387BQ42169112-A2317601-924C-4F10-90E0-69224D51CAB4Q42748175-ECFC9C94-A4F0-41BD-9D79-0CFC04335A5CQ42939096-A5AC726E-DF20-406B-A5A5-4DDD5A0C53E8Q42967126-940A5B21-37F9-4E19-B9A6-F1BBED7F458DQ43072129-E52AC0A6-195D-4141-976A-7221D18F426BQ43259008-341789B0-2823-44BA-8EF3-E1AAB3D301F4Q43262892-4EAA3DCB-1CEB-4904-A51F-F7EF95E8B1C6Q43265104-EB5500E0-DFB3-4ABC-A160-C140C46673D4Q43279923-3F5FD123-1D88-4A61-AF6D-63D1430D43EEQ43290753-7BAA9DC2-390A-479B-8F6A-1701B4EAD530Q43480529-D4A7D452-3083-4960-BFAD-850363728D46Q44777260-AE0659A0-3C40-4D7E-9C25-CCA5ADA31F9BQ44780551-3EB5F98F-7516-45FC-9CD5-413CF43665C5Q44884344-BCF2ECD5-F767-45E2-8F72-338BD96125B2Q45788675-135F23C5-8082-409F-A52A-C927A6F2A6BEQ45841838-F3B87F15-8846-4D67-9490-C9D533F11445Q45925450-41460D54-1B33-4EDE-9C5D-215CCDFCE8BEQ45978004-5530FCD8-81EA-469D-98FB-765E7747BD01Q46031052-36D0039A-AD16-497B-87AA-C54221B9D5DDQ46036722-22457A6A-E806-4CD8-B359-6078A413C3E4Q46080317-6E075861-AD89-4B82-8787-C24626B6C33FQ46113299-BC6611F2-7D8F-44A1-9A5C-0C2930AD6E9FQ46280063-FB6AE2EF-78B6-433C-87DB-4A6791EEDF99Q46313768-F7E3A460-7574-412C-8FDE-96500CA2F79EQ46428215-375D9DF2-840D-4C7B-802B-1045AA96EB00Q46449132-434FAB6E-F538-4856-9B66-88ACF99C4DF5Q46555337-E9C51A84-08E2-4043-B47C-7C24EB7B562BQ46861952-3B56CCC4-171D-4AF5-A952-14A0674D7A3BQ46895250-F00F80F9-1105-427B-91AE-783616D8B254Q46962223-8AA6ED61-402C-47DF-A68C-EDCFD796F998Q47726000-283C47EF-4C2A-424E-9B06-8FE1B550908BQ48218110-40C96542-26B6-4F08-8D0E-9BF52F8CA2ECQ48321588-2F9D1EB9-DDF0-457E-8298-004125C05F45Q51329285-16A26FCF-0025-4503-B1CF-9CCAA215B05BQ51353552-4CA2369A-854E-4C19-AF66-46898B327A03Q53543932-A479C9B2-A496-406A-A96D-947F3F260762Q53577112-400A5847-C046-48E4-BFC0-A42883B101FE
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bulent Uysal
@ast
Bulent Uysal
@en
Bulent Uysal
@es
Bulent Uysal
@sl
type
label
Bulent Uysal
@ast
Bulent Uysal
@en
Bulent Uysal
@es
Bulent Uysal
@sl
prefLabel
Bulent Uysal
@ast
Bulent Uysal
@en
Bulent Uysal
@es
Bulent Uysal
@sl
P106
P1153
16246667700
P31
P496
0000-0003-1254-9749